Matthew Squires

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy Perera, Eleonora Jovcheva, Laurence Mévellec et al. · Molecular Cancer Therapeutics · 2017 · 335 citations · Full text

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

Robert J. Motzer, Camillo Porta, Nicholas J. Vogelzang et al. · The Lancet Oncology · 2014 · 262 citations · Full text

Urology, Oncology, Genitourinary Cancer +7

Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells

Matthew Squires, E A Hudson, Lynne Howells et al. · Biochemical Pharmacology · 2003 · 192 citations

Signal Transduction, Signaling Pathway, Chemoprevention Strategy +14

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

Matthew Squires, Ruth E. Feltell, Nicola G. Wallis et al. · Molecular Cancer Therapeutics · 2009 · 171 citations

Chemoprevention Strategy, Cancer Biology, Tumor Biology +16

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

Reinhard Dummer, Jan C. Brase, James E. Garrett et al. · The Lancet Oncology · 2020 · 151 citations · Full text

Trametinib Versus Placebo, Medicine, Melanoma +10